翻訳と辞書 Words near each other ・ John L. Sullivan (United States Navy) ・ John L. Synge Award ・ John L. Taylor ・ John L. Templeman ・ John L. Connolly ・ John L. Cotter ・ John L. Crain ・ John L. Dagg ・ John L. Davis ・ John L. DeWitt ・ John L. Dorgan ・ John L. Ducker ・ John L. Estrada ・ John L. Finley ・ John L. Fuller ・ John L. Gainer ・ John L. Gardner (boxer) ・ John L. Gardner (brigadier general) ・ John L. Gaunt ・ John L. Georgiou ・ John L. Gibbs ・ John L. Gihon ・ John L. Goldwater ・ John L. Griffith ・ John L. Griffiths ・ John L. Grindell ・ John L. Grove ・ John L. Hagler House ・ John L. Hall ・ John L. Hall, Jr. Dictionary Lists mini英和辞書 mini和英辞書 Webster 1913 Latin-English FOLDOC Wikipedia English ウィキペディア

翻訳と辞書　辞書検索 [ 開発暫定版 ] スポンサード リンク John L. Gainer ： ウィキペディア英語版 John L. Gainer John L. Gainer (born July 19, 1938) is an American chemical engineer and co-founder and chief scientific officer of Diffusion Pharmaceuticals, a biotechnology and pharmaceutical company based in Charlottesville, Virginia, U.S.Gainer pioneered investigation into the mechanism of action underlying oxygen diffusion-enhancing compounds (ODECs) and invented the subclass of ODECs known as bipolar trans carotenoid salts. The lead compound of this class is trans sodium crocetinate (TSC) which Gainer invented while a professor of chemical engineering at the University of Virginia. ==Education and career== Gainer earned a BS in chemical engineering from West Virginia University in 1960, and a PhD in chemical engineering in 1964 from the University of Delaware. He later accepted a professorship in the School of Engineering and Applied Science at the University of Virginia.〔 In the early 1970s, he studied the prediction of diffusion rates of gases in liquids and began to investigate oxygen diffusion in biological systems, focusing particularly on the cardiovascular disease atherosclerosis. While at the University of Virginia, Gainer invented TSC by modifying certain natural products, including saffron, resulting in the creation of a novel single trans isomer carotenoid salt.〔 Using animal models, he then investigated the activity of TSC, exploring his theory that the drug would increase the transfer of oxygen through blood plasma into hypoxic tissues.〔 The drug's clinical promise became evident when Gainer and colleagues demonstrated that TSC could improve survival in animal models of severe hemorrhage while reversing the drop in blood pressure that accompanies the loss of large amounts of blood.〔 From his work with animal models, Gainer also predicted that TSC held promise for the treatment of cancer, stroke, myocardial infarction (heart attack), and other diseases associated with hypoxia and ischemia (a lack of oxygen delivery to tissues). He was awarded the first of over a dozen patents on ODECs and TSC in 2000.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「John L. Gainer」の詳細全文を読む スポンサード リンク 翻訳と辞書 : 翻訳のためのインターネットリソース Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.